MUC1 cytoplasmic tail: a potential therapeutic target for ovarian carcinoma

被引：27

作者：

Hu, Xiu Feng ^{[1
]}

Yang, Eunice ^{[1
]}

Li, Jie ^{[1
]}

Xing, Pei Xiang ^{[1
]}

机构：

[1] Burnet Inst Inc Austin Res Inst, Canc Immunotherapy Lab, Heidelberg, Vic 3084, Australia

来源：

EXPERT REVIEW OF ANTICANCER THERAPY | 2006年 / 6卷 / 08期

关键词：

cancer merastasis; irrisnuinotherapy; MUC1-CT1; signal transduction;

D O I：

10.1586/14737140.6.8.1261

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Ovarian cancer is often a lethal disease, since the occult progression of the tumor within the peritoneal cavity results in late diagnosis and treatment failure. The identification of molecular events specific to metastasis is critical for the development of effective therapies. MUC1 is aberrantly overexpressed by most ovarian cancer and regarded as a molecular target for ovarian cancer. This review focuses on the latest advances regarding a signaling region in the MUC1 C-terminal subunit-mediated c-Src signaling pathways in malignant transformation, invasion and metastasis. Disruption of MUC1-C-terminal subunit-associated c-Src signaling by targeting the specific sites might represent a novel immunotherapeutic approach for the treatment of ovarian cancer.

引用

页码：1261 / 1271

页数：11

共 109 条

[1] MUC1 as a target antigen for cancer immunotherapy [J].

Acres, B ;

Limacher, JM .

EXPERT REVIEW OF VACCINES, 2005, 4 (04) :493-502

[2] Ovarian cancer: Strategies for overcoming resistance to chemotherapy [J].

Agarwal, R ;

Kaye, SB .

NATURE REVIEWS CANCER, 2003, 3 (07) :502-516

[3] Muc1 affects c-Src signaling in PyV MT-induced mammary tumorigenesis [J].

Al Masri, A ;

Gendler, SJ .

ONCOGENE, 2005, 24 (38) :5799-5808

[4] Transition of epithelial toward mesenchymal differentiation during ovarian carcinosarcoma tumorigenesis [J].

Amant, F ;

Vloeberghs, V ;

Woestenborghs, H ;

Moerman, P ;

Vergote, I .

GYNECOLOGIC ONCOLOGY, 2003, 90 (02) :372-377

[5] Identification of protein-tyrosine phosphatase 1B as the major tyrosine phosphatase activity capable of dephosphorylating and activating c-Src in several human breast cancer cell lines [J].

Bjorge, JD ;

Pang, A ;

Fujita, DJ .

JOURNAL OF BIOLOGICAL CHEMISTRY, 2000, 275 (52) :41439-41446

[6] STAT proteins:: From normal control of cellular events to tumorigenesis [J].

Calò, V ;

Migliavacca, M ;

Bazan, V ;

Macaluso, M ;

Buscemi, M ;

Gebbia, N ;

Russo, A .

JOURNAL OF CELLULAR PHYSIOLOGY, 2003, 197 (02) :157-168

[7] The phosphoinositide 3-kinase pathway [J].

Cantley, LC .

SCIENCE, 2002, 296 (5573) :1655-1657

[8] A novel role for FAK as a protease-targeting adaptor protein: Regulation by p42 ERK and Src [J].

Carragher, NO ;

Westhoff, MA ;

Fincham, VJ ;

Schaller, MD ;

Frame, MC .

CURRENT BIOLOGY, 2003, 13 (16) :1442-1450

[9] EGF-related antisense oligonucleotides inhibit the proliferation of human ovarian carcinoma cells [J].

Casamassimi, A ;

De Luca, A ;

Agrawal, S ;

Stromberg, K ;

Salomon, DS ;

Normanno, N .

ANNALS OF ONCOLOGY, 2000, 11 (03) :319-325

[10] C-SRC REGULATES THE SIMULTANEOUS REARRANGEMENT OF ACTIN CYTOSKELETON, P190RHOGAP, AND P120RASGAP FOLLOWING EPIDERMAL GROWTH-FACTOR STIMULATION [J].

CHANG, JH ;

GILL, S ;

SETTLEMAN, J ;

PARSONS, SJ .

JOURNAL OF CELL BIOLOGY, 1995, 130 (02) :355-368

← 1 2 3 4 5 6 7 8 9 10 →